Integrated Wealth Concepts’s Eikon Therapeutics EIKN Stock Holding History

Integrated Wealth Concepts’s Portfolio EIKN Stock Details EIKN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$142K	Buy	+10,900	New	+$111K	﹤0.01%	2278

Other funds holding EIKN

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Foresite Capital Management IV Larkspur, California $290M AUM 143.88% 1-Year Est. Return

Merck & Co Rahway, New Jersey $526M AUM 175.27% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Foresite Capital Management V Larkspur, California $362M AUM 386.37% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

Integrated Wealth Concepts's EIKN Position: Q2 2026 in Review

Integrated Wealth Concepts opened a new position in Eikon Therapeutics (EIKN) in Q2 2026: 10,900 shares worth $142K. The stake represents ﹤0.01% of the portfolio and ranks #2278 among its holdings.

77 funds tracked by Wall St. Rank hold EIKN as of Q2 2026.

Integrated Wealth Concepts held 10,900 shares of Eikon Therapeutics worth $142K as of Q2 2026.
Eikon Therapeutics was a new Integrated Wealth Concepts position in Q2 2026.
Eikon Therapeutics made up ﹤0.01% of Integrated Wealth Concepts's portfolio in Q2 2026, its #2278 holding.
77 funds tracked by Wall St. Rank held Eikon Therapeutics as of Q2 2026.

Based on Integrated Wealth Concepts's 13F filing for Q2 2026, filed 12 Aug 2026.